Life Sciences Archive » November, 2014

Life Sciences - November, 2014

244 articles

• Duane Morris Guides Sex Dysfunction Drug Co.'s Pared IPO
• PTAB Bars Inventor From Proceeding Pro Se In AIA Review
• Ackman Says Allergan Sale May Net $6B For Pershing Square
• 2 Years On, FCA Battles Test Caronia Ruling's Reach
• Medtronic Gets Conditional FTC Nod On $43B Inversion Deal
• Latham Leads November's IPO Action With Work On 8 Deals
• Novartis Sheds Nicotine Patches To Clear Way For Glaxo Deal
• Avandia Insurers Denied Class Cert. In Suit Against Glaxo
• Life Sciences MVP: White & Case's Dimitrios Drivas
• Judge Nixes False-Labeling Suit Over Merck Sunscreens
• 5 Lessons From DOJ's Blockbuster FCA Haul
• Fla. Stock Scheme Atty Sees Post-Trial Motions Rejected
• Pfizer On Sidelines As AstraZeneca Offer Window Opens
• Shire Backers Say AbbVie Execs Lied About Inversion Upside
• Amgen Likely To Be Leading Case Affecting ERISA Pleading
• What To Know About Extending Patent Term In Southeast Asia
• Deals Rumor Mill: BT Group, Bayer, Clarksons
• Market Rumors: GlaxoSmithKline, Keppel, Jasmine Broadband
• 3rd Circ. Won't Revive FCA Suit Against Siemens
• 2nd-Ever Post-Grant Review Ends In Settlement
• Novartis' Painkiller Pricing Strategy Deemed Legal
• Judge Nixes Spine Surgery Patents, Citing Nautilus
• Remembering Doar: Justice As A 4-Letter Word
• CR Bard Pelvic Mesh MDL Plaintiffs Want Suits Combined
• Ex-ArthroCare CEO Wants Retrial Over $756M Fraud Scheme
• Lundbeck CEO Resigns In Ethics Breach Over Outside Shares
• Texas Court Won't Make Zimmer Retry Metal Plate Suit
• Coke, GSK Must Help Clean Up Ohio Site, Supreme Court Told
• Deals Rumor Mill: Glencore, Actavis, Stryker
• Abbott Settles $3.4M Pension Row With Trucking Co.
• Don't Review Invalidation Of Apotex Patent, Fed. Circ. Told
• AstraZeneca Can't End Nexium Pay-For-Delay Trial
• FDA Warns Of Cancer Risk With Uterine Fibroid Surgery Tool
• J&J Unit's Junk Faxes Are Ads, Not Info, Plaintiffs Say
• USTR Stumps For Better IP Protection Ahead Of India Summit
• 'Tis The Season … For Data Breaches And Data Analytics
• Calif. Court Takes On Jurisdiction Dispute In Plavix Suit
• 11th Circ. Asked To Revive Fraud Claims Over Chinese Pharma
• NuScience Atty Tests Judge's Patience At IP Sanctions Hearing
• Nexium Pay-For-Delay Plaintiffs Can't Prove Conspiracy
• Device Cos. Want Separate Twitter Guidance From FDA
• Supplement Co. Nutronics Can't Dodge False-Ad Class Action
• 3rd Circ. Urged To Revive FCA Suit Over Wholesale Drug Costs
• Differentiate Your Litigation Practice With Data Security
• Eli Lilly, Takeda Win Dismissal Of Ark. Taxpayer Actos Suit
• Solace For Wis. Suppliers Over Defective Components
• Is Stockpiling Protected By Hatch-Waxman Safe Harbor?
• Fed Circ. Threatens Sanctions For Redacted Legal Args
• Aeterna Faces Shareholder Suit Over Growth Hormone Drug
• USPTO Official Says New Eligibility Rules Will Quell Fears
• Allergan Hit With $6.5M Verdict In Off-Label Botox Suit
• Roche Wins Ruling At Fed. Circ. On Provitamin Imports
• Judge Scolds Kirkland & Ellis Attys In Ranbaxy-FDA Row
• AstraZeneca Seeks Judgment In Nexium Pay-For-Delay Case
• Genentech Must Pony Up $3M In Mass. Excise Tax
• Valeant Unveils $2B Buyback Plan After Failed Allergan Deal
• Perrigo Plans $900M Offering To Raise Cash For Omega Buy
• $6B Record Haul For DOJ As FCA Reaches New Heights
• SEC Suspends Trading In 4 Stocks, Citing Ebola Fraud Fears
• Boston Scientific Slammed With $18.5M Verdict In Mesh Trial
• J&J, Guidant Trade Barbs In Trial Over Failed $21B Merger
• Sanctions Sought For IP Firm's 'Baseless' $42M Counterclaim
• 2 Assumptions Shape 3rd Circ. Reverse Payment Case
• Novartis FCA Case Reaffirms Importance Of Company Policies
• The Print Room: How To Spend Less And Get More
• Ex-Pfizer Workers Lose Benefits Bid In Suit Over Wyeth Deal
• NIH Seeks Clinical Trial Data For Unapproved Products
• 7th Circ. Slams 'Selfish' $6.5M Deal In Supplement Suit
• Par Pharma Says Its New Drug Won't Rip Off GSK's Lamictal
• Ariosa Gets Stanford DNA Test Patent Nixed In AIA Review
• 3rd Circ. Told Actavis Allows Noncash Settlement Scrutiny
• CR Bard Can't Duck Its Part Of $5.5M Pelvic Mesh Verdict
• Ranbaxy Seeks Mistrial In Nexium Pay-For-Delay Case
• Novartis Can't Send Blood Pressure Suits Home
• Allergan Deal Clouds Rightful Activist Role In Hostile M&A
• DOJ Tallies $25B In Fiscal 2014
• Cancer Biotech Co. Bellicum Pharma Files For $115M IPO
• Royalty Pharma Pays $3.3B For Cystic Fibrosis Drug Royalties
• Law360 MVP Awards Go To Legal Aces From 78 Firms
• Lawyers Tell 8th Circ. To Uphold Jones Day Atty Sanctions
• Novo Nordisk Pays $19M To Settle Prandin Antitrust Action
• AstraZeneca Touts Drug Pipeline Amid Pfizer Bid Speculation
• LifeNet Wins $35M Verdict In Tissue Graft Patent Suit
• French Biotech Files For $100M US IPO To Boost R&D
• 2014 M&A Clears $3T Mark After Allergan, Halliburton Deals
• Reed Smith Atty's Widow Pushes For GSK Docs In Paxil Fight
• En Banc 9th Circ. Reverses Remand Of Teva Painkiller Suits
• CORRECTED: Pharmas Can't Nix Lidoderm MDL Over $170M Pay-For-Delay Deals
• FDA Pushes Back Rule On Generic-Drug Warning Labels
• Fed. Circ. Affirms Warner Chilcott's Actonel Patents Invalid
• Market Rumors: Johnson & Johnson, Roots Group, Alibaba
• Novartis Fights Zometa Jaw Injury Verdict In 11th Circ.
• 5 Ways To Boost An IPO For A No-Profit, Low-Revenue Issuer
• Lab Group Taps Paul Clement, Laurence Tribe For FDA Battle
• Abbott Labs Wants Trucking Co. Atty DQ'd In Contract Row
• GSK Tells 3rd Circ. Avandia RICO Claims Don't Hold Up
• Medtronic Confirms $42.9B Covidien Inversion On Track
• Zoetis Launches $500M Share Buyback As Activists Circle
• Actavis Reveals Allergan Breakup Fee, Board Picks
• Dewey Partner Clawback Ruling May Hurt New York Law Firms
• Pushback Prompts FDA To Propose New Food Safety Rules
• W.Va. Jury Finds Takeda Destroyed Key Actos Documents
• Citing Soul Hit, 11th Circ. Affirms $1.3M Axiom TM Win
• ALJ Stubs Out Fla. Lottery Plan For Medical Pot Dispensers
• Original-Patent Rule Dooms Drug Injection Complaint
• 5 Must-Know Facts About Allergan's $66B Actavis Tie-Up
• 3rd Circ. To Decide If Reverse Payments Must Be Cash
• Hearing Aid Maker Sonova Launches $518M Share Buyback
• Ranbaxy Sues FDA Over Nixed Approvals Of Generics
• Pfizer, Merck Reach $2.9B Deal To Develop Cancer Drug
• Biopharma Co. Juno Seeks IPO To Expand Cancer Drug R&D
• Abbott Unloads Animal Health Biz In $255M Zoetis Deal
• Post-Grant Review May Impact Biosimilars Litigation
• Allergan Finds White Knight In $66B Actavis Takeover
• Kilpatrick Urges Toss Of Medication-Cart IP Theft Claims
• SEC Wants $602M SAC Settlement To Go To Victims
• Valeant Disclosures Approved In Allergan Inside Trading Row
• Drug Return Co., Execs Plead Not Guilty To $116M Fraud
• 4 Things To Know As Feds Ditch 340B 'Mega Rule'
• Pharma Exec Can't Duck SEC's Pump-And-Dump Suit
• Biomerieux Sinks Lab's Suit Over Faulty Testing System
• Pliva Asks High Court To Review Generic Drug Ruling
• Market Rumors: Medtronic, Pemex, Beijing Infrastructure
• Philips Wants To Drain $467M Blood Sensor IP Verdict
• Deals Rumor Mill: Hostess, Azadea, Pfizer
• Vascular Solutions, CEO Indicted For Unapproved Sales
• Whole Foods Tries To 'Pick Off' Homeopathy Class Action
• Minority Powerbrokers Q&A: Weil's Laura Wilkinson
• Biotech Co. FibroGen Raises $146M In Upper Range IPO
• ITC Trends Medical Device Companies Should Know About
• Boston Scientific Hit With $27M Bellwether Mesh Verdict
• Ethicon Gets 76 Pelvic Mesh Users' Claims Nixed In Texas
• Liberty Medical Wins Approval For $68.5M Bankruptcy Sale
• Abbott Wants HIV-Drug Fight With GSK Narrowed For Retrial
• 5 Reasons Israeli Cos. Are Flirting With US Markets
• Allergan Slams Proposed Disclosures In Insider Trading Suit
• Dr. Reddy's Denied Quick Win In Consultant Noncompete Row
• Class Certified In GNC Wage Statement Suit
• Jury Clears J&J Unit In Children's Tylenol Suit
• Questcor Securities Class Clinches Certification
• Derivative Suit Faults Allergan Board For Rejecting Valeant Bid
• PRA Health Sciences Raises $305M After IPO Misses Mark
• CLOs: Fight Fraud With Better Analytics
• The Latest Life Sciences Company To Make FCPA Headlines
• Bankrupt Dendreon Eyes Possible Auction In February
• Allergan Wants Miotox Patent Invalidated In $600M Botox Row
• Panel To Probe Dickstein Shapiro's Wooing Of AG
• Medtronic Offers EU Concessions On $43B Covidien Bid
• Reglan Failure-To-Warn Claims Not Preempted, NJ Court Says
• DOJ's Investigation Into Generic Pharma Pricing Is Unusual
• Braintree Asks High Court To Hear Claim Construction Row
• Don't Read Too Much Into AbbVie Case, FTC's Feinstein Says
• DaVita Hit With Sanction Request In Kidney Drug FCA Suit
• Bankrupt Natrol Gets Nod For $132.5M Sale To Aurobindo
• Allergan Amends Bylaws Ahead Of Potential Proxy Fight
• Context Is Key For Sunshine Payments Under ACA
• Becton Must Pony Up $340M In Syringe Antitrust Suit
• Aurobindo Blows Away Natrol Stalking Horse With $132M Bid
• Chicago Hits Back At Drugmakers' Cohen Milstein DQ Bid
• Attys' Fee Award Cut To $91M In Pfizer Neurontin MDL
• Deals Rumor Mill: Solvay, Time Warner, Too Faced Cosmetics
• Drug Cos. Seek Judgment In Nexium Pay-For-Delay Case
• King & Spalding Adds Ex-FDA Medical Device Ace In DC
• Cancer Drug Maker Dendreon Hits Ch. 11 Hoping To Sell
• Japanese Medical Device Rules Stress Speed, Uniformity
• Del. Court Is 1st To Apply Daimler To Hatch-Waxman Case
• Lilly Defeats Cymbalta Label Suit As Possible MDL Looms
• Class Wins Partial Cert. In Flu Remedy Labeling Suit
• 9th Circ. Delivers Partial Win For Baby Gender Prediction Co.
• Taxation With Representation: Cravath, Vinson, Cooley
• Allergan Shareholder Claims Not Ripe, Chancery Rules
• Biotronik Pays $4.9M To Settle FCA Kickback Claims
• Weil Reps Advent, Avista In $1.5B Spinout Of UCB Pharma Co.
• Probiotic False Ad Class Action Against Bayer Survives
• Clinical Development Co. INC Research Raises $150M In IPO
• Ackman Says Valeant Can Pay Max Bid For Allergan
• FDA Accused Of Failing To Fully Vet Animal Growth Drugs
• Allergan Decision May Chill Bidder-Activist Partnerships
• $1B Stryker Deal Shows Path To Trial-Free MDL Settlements
• Nature Made Supplement Buyers Near Cert. In False Ad Suit
• FDA Yanks Ranbaxy's Approvals For Generic Nexium, Valcyte
• Cephalon Wants FCA Off-Label Suits Heard Separately
• 3rd Circ. Urged To Rethink Reviving Genaera Investor Suit
• SEC May Question Journalist In Onyx Insider Trading Probe
• Allergan Confirms Deal Talks With Potential New Suitor
• Calif. Med Tech Co. Nevro Raises $126M In Upsized IPO
• FDA Issues Warning To Sciecure Over Insomnia Drug Promo
• Applera Urges Fed. Circ. To Nix Enzo DNA Patent Win
• Market Rumors: Drybar, Bojangles, Walgreen
• Why Big-Ticket Deal Failures Don't Spell Trouble For M&A
• Enzymotec Investors Want Suits Over $70M IPO Combined
• Siemens Abandons Spinoff IPO For $2.7B Private Sale To EQT
• Perrigo Pays €3B For Bigger Slice Of Buzzing OTC Drug Space
• AstraZeneca CEO Says Inversion Rules Undercut Pfizer Bid
• 5 Ways To Uncover Bias During Jury Selection
• Secondary Considerations For Pharma Patents Get 2nd Look
• Broker Pleads Guilty After SEC BigLaw Tipster Case
• Endo, Teikoku Monopoly Claims Likely Out In Lidoderm MDL
• FDA Sued Over Detained Chinese Leg Braces
• 9 Votes On Health Ballot Measures You Might Have Missed
• ACA's Med Device Tax Causes Scant Harm, Report Says
• Robbins Arroyo Investigates Bio-Rad After $55M FCPA Deal
• Pfizer Nixes Pharmacists' Claims In Lipitor Pay-To-Delay Row
• Wash. Tax Board Rules Medical Weed Subject To Sales Tax
• A-Rod Admitted To Using Steroids, Bought Cousin's Silence
• How Senate Without Filibuster-Proof Majority Avoids Gridlock
• Walgreen Blood Tester Throws Down Gauntlet In Rival TM Row
• NLRB Judge Faults McKesson Over Plot To Decertify Union
• Nexium Buyers Seek Litigation Docs From AstraZeneca
• Confidential Witness Denies Testimony In Remoxy Suit
• FDA Asks Court To Stop Dietary Supplement Co. Sales
• In Allergan Insider Trade Ruling, Questions Upstage Answers
• Pfizer Says Plaintiffs In Zoloft MDL Can't Prove Causation
• Fresenius Brings Antibiotics Row With Cubist To PTAB
• Endocyte Investor Sues Over Faulty Drug In $1B Merck Deal
• Gene Therapy Co. Xenon Pharma Misses Target In $36M IPO
• Venture-Backed Glaucoma Co. Seeks To Raise $86.3M In IPO
• GOP Poised To Slow Down Obama Product Safety Measures
• GOP Senate Will Press FDA To Ease Up
• FDA Urged To Ban Drug Coating Chemical
• J&J Wins Dismissal Of Listerine False Labeling Suit
• High Court Likely Won't Affirm 6th Circ. Omnicare Ruling
• Royal DSM To Unload 3 Biz Units Amid Investor Pressure
• ICV Partners Presents $84M Offer For Bankrupt Natrol
• FDA Backs Tougher Warnings For Nexium, Prilosec
• Ackman Can Vote Allergan Shares Amid Insider Trading Flap
• Ex-Orioles Player Calls Insider Trading Charges 'Stale'
• Double Patenting: Old Tool For Generics And Biosimilars
• Stryker To Pay $1B To Settle Hip Implant MDL Claims
• Generic Drug Patent Cases On The Rise In 2014, Report Says
• Dentons Nabs Four Insurance Litigators From Riker Danzig
• Pa. Woman Says Shire Dumped Her For Whistleblowing
• CMS Axes Sunshine Act Exemption For Continuing Education
• Calls Grow For Fed. Circ. To Eye Laches Post-'Raging Bull'
• Expert In Pelvic Mesh MDL Shouldn't Be DQ'd, Plaintiffs Say
• 2 Biotechs Polish IPO Plans As Market Heats Back Up
• 3rd Circ. OKs FTC To Join Lamictal Oral Arguments
• Bio-Rad Pays $55M To Settle Feds' FCPA Investigations
• KKR-Backed Clinical Trials Co. Sets Terms For $400M IPO
• Allergan Says New Suitor Approached It About A Deal
• J&J Heir Wants Proskauer Documents In Tax Shelter Suit
• LabCorp Acquires Covance In $6.1B In Cash-Stock Deal
• Bristol-Myers V. Teva: What Doomed The Entecavir Patent
• Digesting The FDA's Changes To Animal Food Regulations